奥氮平预防腹盆腔放疗所致恶心呕吐的III期随机安慰剂对照试验
这项前瞻性双盲III期随机安慰剂对照研究评估奥氮平预防腹盆腔放疗期间恶心呕吐(RINV)的疗效,共随机301例患者,比较5HT3拮抗剂联合奥氮平5mg每日一次与联合安慰剂的差异。结果显示奥氮平组无/轻微恶心事件比例显著更高(85.8% vs 16.3%,p<0.001),呕吐控制、补救治疗需求及≥2级恶心呕吐均显著改善,不良反应以1级为主,无4/5级毒性。
要点
- 奥氮平5mg联合标准止吐药使无/轻微恶心比例从16.3%提升至85.8%(p<0.001)。
- 奥氮平组补救止吐治疗需求仅1.4%,显著低于安慰剂组7.8%(p=0.008)。
- 不良事件以1级嗜睡、构音障碍、体位性低血压为主,无4/5级毒性。
核心结论
- 在标准止吐药基础上加用奥氮平5mg每日一次,可显著减少腹盆腔放疗期间的恶心呕吐。
研究设计与样本
- 前瞻性、双盲、III期随机安慰剂对照研究,2022年2月至2024年8月共随机301例接受腹盆腔放疗且无既往放疗史的患者。
- 患者随机接受奥氮平5mg每日一次(n=148)或安慰剂(n=153),均联合昂丹司琼4mg每日两次。
- 主要终点为恶心预防,次要终点包括呕吐控制、补救药物使用、毒性、焦虑抑郁及生活质量。
主要发现
- 放疗期间无/轻微恶心事件比例:奥氮平组85.8%,安慰剂组16.3%(p<0.001)。
- 无/轻微呕吐事件比例:奥氮平组95.9%,安慰剂组74.5%(p<0.001)。
- 呕吐≥15次的患者比例:安慰剂组9.2%,奥氮平组2%(p=0.001)。
- 需要补救治疗的比例:安慰剂组7.8%,奥氮平组1.4%(p=0.008)。
- ≥2级恶心发生率:安慰剂组67%,奥氮平组7.4%(p=0.001);≥2级呕吐发生率:安慰剂组7.8%,奥氮平组1.4%(p=0.001)。
关键数值与推荐
- 直肠癌患者中≥2级恶心发生率:安慰剂组85.7%,奥氮平组2.8%(p=0.001)。
- 同步放化疗患者中恶心发生率:安慰剂组94.3%(82例),奥氮平组12.6%(10例)(p<0.001)。
- 同步放化疗患者中呕吐发生率:安慰剂组32.2%(28例),奥氮平组6.3%(5例)(p<0.001)。
- 奥氮平组1级不良反应包括嗜睡(p<0.001)、构音障碍(p=0.003)、体位性低血压(p<0.001),未观察到4/5级毒性。
- 放疗后EORTC GHS生活质量平均分:标准组61.6±8.6,实验组62.9±9.2(p=0.235)。
临床怎么用
- 对于接受腹盆腔放疗的患者,可考虑在标准5HT3止吐药基础上加用奥氮平5mg每日一次以预防恶心呕吐。
- 奥氮平组1级嗜睡、构音障碍和体位性低血压较常见,用药期间需关注相关症状。
局限性
- 研究未报告其他潜在局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prospective, double-blind, phase III randomized placebo-controlled study evaluated the efficacy of olanzapine in preventing RINV during abdominal-pelvic radiation therapy. METHODS: Patients receiving abdominal/pelvic RT without prior radiation were randomized to receive either olanzapine 5 mg or placebo once daily, alongside standard ondansetron (4 mg BID). Primary endpoint was nausea prevention; secondary endpoints included emesis control, rescue medication use, toxicity, anxiety, depression, and quality of life (QOL). RESULTS: Between Feb 2022 and Aug 2024, 301 patients were randomized to 5HT3 + placebo (n = 153) or 5HT3 + olanzapine (n = 148). Baseline characteristics were comparable. During radiation therapy treatment, proportion of patients with 'no/ minimal' nausea events in 5HT3 + Olanzapine arm was 85.8% and in 5HT3 + placebo arm was 16.3% (p < 0.001) respectively. Similarly, 'no/minimal' vomiting events reported in 5HT3 + Olanzapine arm was 95.9% and in 5HT3 + placebo arm was 74.5% (p < 0.001) respectively. Vomiting episodes ≥ 15 were more in 5HT3 + placebo (9.2%) than 5HT3 + olanzapine (2%; p = 0.001). Rescue therapy required in 7.8% (placebo) & 1.4% (olanzapine) (p = 0.008). Grade ≥ 2 nausea was 67% (placebo) vs 7.4% (olanzapine) (p = 0.001). In rectal cancer, grade ≥ 2 nausea in placebo & olanzapine arms were 85.7% & 2.8% (p = 0.001). Nausea in concurrent chemoradiation was higher in placebo 82(94.3%) vs olanzapine 10(12.6%) (p < 0.001). Grade ≥ 2 vomiting occurred in 7.8% (placebo) and 1.4% (olanzapine) (p = 0.001). Vomiting in concurrent chemoradiation was higher in placebo 28(32.2%) vs olanzapine 5(6.3%) (p < 0.001). Adverse reactions (grade 1) in olanzapine arm included drowsiness (p < 0.001), dysarthria (p = 0.003), orthostatic hypotension (p < 0.001). No grade 4/5 toxicity observed. Anxiety and depression reduced significantly (p < 0.001). Mean EORTC GHS QOL score post-RT: 61.6 ± 8.6 (standard) vs 62.9 ± 9.2 (experimental) (p = 0.235). CONCLUSIONS: Adding olanzapine 5 mg with standard antiemetics significantly reduced RINV during abdominal-pelvic radiation therapy.
引用
- Vijayan M, Narmadha MP, Nair H, et al. Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI/2022/01/039723. Radiother Oncol. 2026. PMID: 42119640. doi:10.1016/j.radonc.2026.111571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。